Stock listing
NASDAQ:IAM Iambic Therapeutics, Inc. Stock
Home listing (NASDAQ) of Iambic Therapeutics, Inc.
Follow Iambic Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IAM
$13.11 USD -1.65 (-11.2%)
Close on Nov 20, 2026
- Day range
- $12.77 – $14.00 USDNov 20, 2026
- Volume
- 281,909 sharesNov 20, 2026
- Market cap
- $621.4M USDAt the close on Nov 20, 2026 · price × 47.40M shares outstanding
- Traded on an average day
- $11.91M USDMedian day 480,276 shares · last 3 months, Oct 15, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IAM · Home | $13.11 USD | -1.65 (-11.2%) | 281,909 | $13.98 | $14.00 | $12.77 | $14.76 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Oct 15, 2026 – Nov 20, 2026 · NASDAQ:IAM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.11 | -1.65 | -11.2% | $13.98 | $14.00 | $12.77 | 281,909 | |
| $14.76 | +0.54 | +3.8% | $15.00 | $15.42 | $14.10 | 376,015 | |
| $14.22 | +2.37 | +20.0% | $11.97 | $14.71 | $11.58 | 481,652 | |
| $11.85 | -1.25 | -9.5% | $12.69 | $12.94 | $11.35 | 456,377 | |
| $13.10 | -1.74 | -11.7% | $14.90 | $15.06 | $12.68 | 277,675 | |
| $14.84 | -0.545 | -3.5% | $15.39 | $15.39 | $14.02 | 488,739 | |
| $15.39 | +0.605 | +4.1% | $14.87 | $15.85 | $13.96 | 364,830 | |
| $14.78 | +1.40 | +10.5% | $14.47 | $15.01 | $12.80 | 867,820 | |
| $13.38 | +3.21 | +31.6% | $10.06 | $13.47 | $9.90 | 899,208 | |
| $10.17 | -1.47 | -12.6% | $11.52 | $11.84 | $9.60 | 671,700 | |
| $11.64 | -1.76 | -13.1% | $13.16 | $13.22 | $10.55 | 751,300 | |
| $13.40 | -0.09 | -0.7% | $13.80 | $13.96 | $13.15 | 293,400 | |
| $13.49 | +0.53 | +4.1% | $13.10 | $13.74 | $12.43 | 220,300 | |
| $12.96 | -0.47 | -3.5% | $13.43 | $13.55 | $12.02 | 402,700 | |
| $13.43 | -0.85 | -6.0% | $13.10 | $13.57 | $12.39 | 476,700 | |
| $14.28 | -0.50 | -3.4% | $14.79 | $14.96 | $13.76 | 270,100 | |
| $14.78 | +0.78 | +5.6% | $13.84 | $16.50 | $13.60 | 925,300 | |
| $14.00 | -0.41 | -2.8% | $14.41 | $14.90 | $13.51 | 439,700 | |
| $14.41 | +0.15 | +1.1% | $14.40 | $15.25 | $14.00 | 149,000 | |
| $14.26 | -0.41 | -2.8% | $14.50 | $14.64 | $13.02 | 609,600 | |
| $14.67 | -1.13 | -7.2% | $15.40 | $15.47 | $14.50 | 495,900 | |
| $15.80 | -0.21 | -1.3% | $15.50 | $17.06 | $15.00 | 478,900 | |
| $16.01 | -0.33 | -2.0% | $16.31 | $17.50 | $15.00 | 980,600 | |
| $16.34 | -7.47 | -31.4% | $21.00 | $21.54 | $14.10 | 2,382,700 | |
| $23.81 | +4.90 | +25.9% | $19.31 | $25.00 | $19.31 | 2,964,900 | |
| $18.91 | — | — | $16.15 | $19.70 | $16.15 | 2,009,400 |
- Ticker
- NASDAQ:IAM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Iambic to participate in Jefferies Global Healthcare Conference
Latest news
Iambic to participate in Jefferies Global Healthcare Conference
Nov 9, 2026
Closed $13.38 (+31.6%) on Nov 9, 2026
Iambic Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 9, 2026 · oldest 2026
Where Iambic Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IAM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IAM | BOATS | United States | USD |
Valuation
EV/sales 39.2× against a median of 5.5×: 6th lowest of 8 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $369.4M USD
- P/E
- Loss
- EV/sales
- 39.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Not reported
- Operating margin
- −873.6%
- Net margin
- −820.0%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Iambic Therapeutics, Inc. · NASDAQ:IAM | US$621.4M | US$369.4M | n/a | 39.2× | n/a | n/a | −820.0% | n/a | n/a |
| Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197 | US$647.2M | US$565.0M | n/a | 37.8× | n/a | 6.8× | −18.6% | 0.0× | n/a |
| Prime Medicine, Inc. · NASDAQ:PRME | US$645.8M | US$695.1M | n/a | 98.4× | n/a | 76.5× | n/a | 13.1× | 2.28 |
| Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT | US$638.7M | US$404.3M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.96 |
| Gubra A/S · OMXCOP:GUBRA | US$638.5M | US$533.6M | 2.6× | 1.4× | 1.7× | 4.2× | 64.1% | 0.2× | n/a |
| Kura Oncology, Inc. · NASDAQ:KURA | US$634.9M | US$152.6M | n/a | 1.9× | n/a | 35.4× | −369.3% | 0.6× | 1.30 |
| Alphamab Oncology · HKEX:9966 | US$628.9M | US$454.7M | n/a | 5.5× | n/a | 2.5× | −20.1% | 0.2× | n/a |
| Janux Therapeutics, Inc. · NASDAQ:JANX | US$616.7M | −US$308.6M | n/a | −13.3× | n/a | 0.7× | −428.7% | 0.0× | 0.95 |
| Olema Pharmaceuticals, Inc. · NASDAQ:OLMA | US$615.0M | US$204.6M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.25 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.6M | n/a | 106× | n/a | 2.9× | n/a | 0.4× | n/a |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Median of the others | US$631.9M | US$439.2M | 2.6× | 5.5× | 1.7× | 3.5× | −20.1% | 0.2× | 1.47 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 27.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.51 · 3 analysts
- Revenue, year to Dec 2026
- 75.87M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Tom Miller | Co-Founder and Chief Executive Officer |
| Michael Secora | Chief Financial Officer and Chief Corporate Development Officer |
| Sunny Chang | General Counsel |
| Laurent Gomez | Senior Vice President and Head of Discovery |
| Matt Welborn | Senior Vice President, Machine Learning |
| Fred Manby | Co-Founder and Chief Technology Officer |
| Neil Josephson | Chief Medical Officer |
| Pete Olson | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| William Rastetter | Board Chair |
| Evan Rachlin | Board Member |
| Jacob Vogelstein | Board Member |
| Kurt von Emster | Board Member |
| Mary Tagliaferri | Board Member |
| Samit Hirawat | Board Member |
| Shalini Sharp | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −9.5% |
IPO
Priced at US$16.00 a share on Oct 14, 2026.
- Price
- US$16.00 a share
- Shares offered
- 9,375,000 shares of common stock
- Offering size
- US$150 million
- Underwriters' option
- Up to 1,406,250 more shares
- Listing
- IAM on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Jefferies, BofA Securities, Citigroup · In the order on the cover
- Shares delivered
- On or about Oct 16, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 24, 2026 |
| Filed publicly | Sep 21, 2026 |
| Amended once | Oct 8, 2026 |
| Shares registered with an exchange | Oct 13, 2026 |
| Declared effective by the SEC | Oct 14, 2026 |
| Final prospectus, with the price | Oct 15, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 15, 2026 |
| EFFECT · Notice that a registration is effective | Oct 14, 2026 |
| CERT · Exchange's certificate of listing | Oct 14, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 13, 2026 |
| S-1/A · Registration statement, amended | Oct 8, 2026 |
| S-1 · Registration statement | Sep 21, 2026 |
| DRS/A · Draft registration statement, amended | Aug 28, 2026 |
| DRS · Draft registration statement | Jul 24, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 15, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 9.43M | 1.19M |
| Research and development | 77.5M | 45.7M |
| Selling, general and administrative | 14.2M | 9.38M |
| Operating income | -82.3M | -53.9M |
| Depreciation and amortization | 1.23M | 1.06M |
| EBITDA | -81.1M | -52.8M |
| Interest expense | 17.0K | 8.00K |
| Income before tax | -77.3M | -47.8M |
| Net income | -77.3M | -47.9M |
| Earnings per share, basic | -1.63 | -1.01 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 180.5M | 141.6M |
| Receivables | 1.32M | 444.0K |
| Current assets | 183.6M | 143.9M |
| Total assets | 195.0M | 155.7M |
| Accounts payable | 3.32M | 2.88M |
| Current liabilities | 26.3M | 16.9M |
| Total liabilities | 381.6M | 268.0M |
| Shareholders' equity | -186.6M | -112.2M |
| Shares outstanding | 47.4M | 47.4M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -58.8M | -33.6M |
| Capital spending | -1.28M | -707.0K |
| Free cash flow | -60.1M | -34.3M |
| Cash from financing | 99.1M | 65.0M |
| Change in cash | 39.0M | 30.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 19, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
All 49 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 424B4 · Prospectus | Oct 15, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 15, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 14, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 14, 2026 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Oct 14, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Oct 13, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 8, 2026 | Offer document | SEC |
| S-1 · Registration statement | Sep 21, 2026 | Offer document | SEC |
| D | Sep 9, 2026 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Aug 28, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Jul 24, 2026 | Offer document | SEC |
| D | Apr 8, 2026 | Other filings | SEC |
| D | Nov 21, 2025 | Other filings | SEC |
| D/A | Jun 6, 2024 | Other filings | SEC |
| D/A | May 7, 2024 | Other filings | SEC |
| D | Apr 25, 2024 | Other filings | SEC |
| D | Oct 12, 2023 | Other filings | SEC |
Cap table
Built by 6ix from Iambic Therapeutics, Inc.’s releases
- Common shares
- 47,400,796
- Fully diluted
- 47,400,796
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 47,400,796 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 47,400,796 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William H. Rastetter Other companies: Dare Bioscience, Inc. (Chairman of the Board · Since at least Jun 30, 2026); Neurocrine Biosciences, Inc. (Director · Since at least May 21, 2026); Fate Therapeutics, Inc. (Chairman · Since at least May 5, 2026) | Board Chair · Since at least Oct 16, 2026 |
| Shalini Sharp Other companies: Neurocrine Biosciences, Inc. (Director · Since at least Apr 15, 2026) | Board Member · Since at least Nov 5, 2026 |
| Evan Rachlin | Board Member · Since at least Oct 16, 2026 |
| Fred Manby | Co-Founder and Chief Technology Officer · Since at least Nov 4, 2026 |
| Jacob Vogelstein | Director · Since at least Oct 16, 2026 |
| Kurt von Emster | Board Member · Since at least Nov 5, 2026 |
| Laurent Gomez | Senior Vice President and Head of Discovery · Since at least Nov 4, 2026 |
| Mary Tagliaferri | Board Member · Since at least Nov 5, 2026 |
| Matt Welborn | Senior Vice President, Machine Learning · Since at least Nov 4, 2026 |
| Michael Secora | CFO & Chief Corp Dev Ofcr · Since at least Oct 16, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Neil Josephson | Chief Medical Officer · Since at least Oct 26, 2026 |
| Pete Olson | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Samit Hirawat | Board Member · Since at least Nov 5, 2026 |
| Sunny Chang | General Counsel · Since at least Nov 4, 2026 |
| Tom Miller | Co-Founder and Chief Executive Officer · Since at least Oct 26, 2026 |
Log in to ask 6ix AI your own questions about Iambic Therapeutics, Inc.